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1. Introduction 
The main purpose of the gastrointestinal tract is to digest and absorb nutrients (fat, 
carbohydrates, and proteins), micronutrients (vitamins and trace minerals), water, and 
electrolytes. Digestion involves both mechanical and enzymatic breakdown of food. 
Mechanical processes include chewing, gastric churning, and the to-and-fro mixing in the 
small intestine. Enzymatic hydrolysis is initiated by intraluminal processes requiring gastric, 
pancreatic, and biliary secretions. The final products of digestion are absorbed through the 
intestinal epithelial cells.  
Malabsorption is a state arising from abnormality in absorption of food nutrients across the 
gastrointestinal (GI) tract. Depending on the abnormality, impairment can be of single or 
multiple nutrients leading to malnutrition and a variety of anaemias. Symptoms of 
malabsorption are varied because the disorder affects so many systems. General symptoms 
may include loss of appetite (anorexia), weight loss, fatigue, shortness of breath, 
dehydration, low blood pressure, and swelling (edema). Nutritional disorders may cause 
anemia (lack of iron, folate and vitamin B12), bleeding tendency (lack of vitamin K), or bone 
disease (lack of vitamin D). Gastrointestinal symptoms include flatulence, stomach 
distention, borborygmi (rumbling in the bowels), discomfort, diarrhea, steatorrhea 
(excessive fat in stool) and frequent bowel movements (Bai, 1998). Intestinal malabsorption 
can be due to : mucosal damage (enteropathy), congenital or acquired reduction in 
absorptive surface, defects of specific hydrolysis, defects of ion transport, impaired 
enterohepatic circulation or pancreatic insufficiency (Walker-Smith & al.,2002). This chapter 
will particularly focus on fat malabsorption, the overriding problem caused by severe 
pancreatic insufficiency. 
Pancreatic insufficiency is a condition commonly associated with diseases such as 
pancreatitis or cystic fibrosis. Patients suffering from these pathologies show a shortage of 
the digestive enzymes necessary to break down food. Hence, a common feature of these 
diseases is a severe dietary malabsorption due to the poor hydrolysis of lipid in the lumen of 
small intestine. Digestive lipases are the key enzymes of fat digestion. The most common 
example of these enzymes is human pancreatic lipase. Nevertheless, the human lipases 
include the pre-duodenal lingual and gastric lipase, the extra-duodenal pancreatic, hepatic, 
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lipoprotein and the recently described endothelial lipase. In this chapter, a short basic 
overview of these fat-digesting enzymes and their physiological contribution to fat digestion 
is first presented. Thereafter, pathophysiology of fat malabsorption resulting from exocrine 
pancreatic insufficiency, clinical symptoms, incidence and diagnosis of the pathology are 
described as well. 
Standard strategies for exocrine pancreatic insufficiency management are based on oral 
administration of porcine derived pancreatic extracts. Unfortunately, this approach is being 
unsatisfactory for many reasons. Greater attention has been paid over the last decade to 
optimize correction of fat malabsorption and essential fatty acid deficiency in order to 
improve the quality of life and extend the life span of patients with severe pancreatic 
insufficiency. Hence, we interestingly discuss herein drawbacks of therapeutic use of 
currently available lipase preparations before focusing mainly on research forces joined for 
the development of new oral enzyme substitution approaches and future promising 
opportunities to treat intestinal fat malabsorption caused by exocrine pancreatic 
insufficiency. 
2. Human digestive lipases 
Lipases are key enzymes responsible for digesting lipids in the digestive system. In humans, 
gastrointestinal lipases include pre-duodenal lipases (gastric lipase and lingual lipase) and 
the other members of the lipase gene family: pancreatic, hepatic, lipoprotein and endothelial 
lipases. The chromosomal localization of genes encoding these lipases and their tissue of 
origin has been described (Table 1).  
 
Lipase Chromosomal localization 
of gene 
Tissue of origin References 
Lingual lipase -* Serous glands of the 
tongue 
Hamosh, 1990 
    
Gastric lipase 10q23.2 Fundic mucosa of the 
stomach 
Bodmer & al., 
1987 
 
Pancreatic lipase 10q26.1 Pancreas Sims & al., 1993 
 




8p22 Adipose, heart, skeletal 
muscle 
Wion et al., 1987 
Endothelial 
lipase  
18q21.1 Endothelial cells, liver, 
lung, kidney, placenta 
Hirata et al., 1999 
* Unknown data 
Table 1. Human digestive lipases  
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2.1 Lingual lipase 
The serous von Ebner glands of the tongue secrete lingual lipase in the saliva. Unlike 
rodents, lingual lipase is present in trace amounts in humans (Hamosh, 1990). Human lipase 
purified from lingual serous glands or gastric juice has a MW of 45 kDa to 51 kDa but tends 
to aggregate (MW 270-300 kDa and 500 kDa) and is highly hydrophobic (Hamosh, 1990). 
Lingual lipase has unique characteristics including an optimum activity at pH 4,5 – 5,4 and 
ability to catalyze reactions without bile salts (Hamosh & Scow, 1973). Lingual lipase breaks 
down short and medium chain saturated fatty acids and helps in their digestion. It has been 
stated that 10 to 30% of dietary fat is hydrolyzed in the stomach by lingual lipase. The 
enzyme uses a catalytic triad consisting of Aspartatic Acid-203 (Asp), Histidine-257 (His), 
and Serine-144 (Ser), to initiate the hydrolysis of a triglyceride into a diacyglyceride and a 
free fatty acid (Hamosh & Scow, 1973). Secreted in the buccal cavity, lingual lipase is one of 
the key components that make the digestion of milk fat in newborns possible. In humans 
lipolytic activity is present in gastric aspirates as early as 26 weeks of gestational age which 
is evidence enough for the fact that lingual lipase is present at birth (Hamosh, 1979). New 
born infants indeed secrete only low amounts of pancreatic lipase and bile salts and it has 
been demonstrated that pancreatic lipase alone does not readily hydrolyze a lipid emulsion 
as well as native milk fat globules (Miled & al., 2000). 
2.2 Gastric lipase 
Gastric lipase (EC 3.1.1.3) is the predominant pre-duodenal lipase in humans. The enzyme is 
secreted in the gastric juice by the chief cells of fundic mucosa in the stomach (Moreau & al., 
1988). The pre-duodenal enzyme was purified from human gastric aspirates and its N-
terminal amino-acid sequence was determined. The amino-acid sequence from the isolated 
protein and the DNA sequence obtained from the cloned gene indicated that human gastric 
lipase consists of a 379 amino acid unglycosylated polypeptide with a molecular weight of 
43 162 Da (Bodmer & al., 1987). However, native human gastric lipase (HGL) (molecular 
weight 50 kDa) is a highly glycosylated protein with four potential glycosylation sites 
(Bodmer & al., 1987). Human gastric and rat lingual lipase share a high degree of sequence 
homology and have identical gene organizations (Lohse & al., 1997). Gastric lipase belongs 
to the ǂ/ǃ-hydrolase-fold family. It possesses a classical catalytic triad (Ser-153, His-353, 
Asp-324) and an oxyanion hole (backbone NH groups of Gln-154 and Leu-67) analogous to 
serine proteases (Roussel & al., 1999). It has an optimum pH activity around 5.4, hydrolyzes 
long-, medium- and short-chain triacylglycerols and do not require bile acid or colipase for 
optimum enzymatic activity (Denigris et al., 1985). For many years, the exact physiological 
contribution of gastric lipase to the overall process of lipolysis was unknown. Carrière et al. 
(1993a) established, for the first time, that most of the HGL secreted in the stomach was still 
active in the duodenum. They estimated that the gastric lipase contribution in the hydrolysis 
of triglycerides is about 25 %. The stereoselectivity of HGL toward triglycerides was also 
investigated. It was clearly demonstrated that HGL shows a stereopreference for the sn-3 
position of the triglyceride (Rogalska & al., 1990).  
Hence, gastric lipase, together with lingual lipase, make up 30% of lipid hydrolysis occurring 
during digestion in the human adult, with gastric lipase contributing the most of the two 
acidic lipases. In neonates, these acidic pre-duodenal lipases are much more important, they 
have the unique ability to initiate the degradation of maternal milk fat globules. 
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2.3 Pancreatic lipases 
A limitation of acidic lipases is that they remove only one fatty acid from each 
triacylglycerol. The free fatty acid can readily cross the epithelial membrane lining the 
gastrointestinal tract, but the diacylglycerol cannot be transported across. Hence, hydrolysis 
of dietary triacylglycerols by both gastric and pancreatic lipase is essential for their 
absorption by enterocytes. Human pancreatic lipase (HPL) (EC 3.1.1.3) is produced by the 
pancreatic acinar cells. The lipase is located into the zymogen granules, together with many 
other enzymes and secreted into the intestinal lumen together with the bile (Miled & al., 
2000). Contrary to most of the pancreatic enzymes which are secreted as proenzymes and 
further activated by proteolytic cleavage in the small intestines, HPL is directly secreted as 
an active enzyme. Purified from pancreatic juice, the protein showed to have a molecular 
weight of 48 kDa (De Caro & al., 1977) and has been characterized as a glycoprotein 
consisting of 449 amino acid polypeptide (Lowe & al., 1989). The resolution of the HPL 3D 
structure (Fig.1) revealed the presence of a catalytic triad (Ser152-Asp176 –His263) similar to 
that found in other serine hydrolases, Ser l52 being part of the G-X-S-X-G consensus sequence 
(Lowe & al., 1989). Pancreatic lipase acts maximally around pH 8-9 (Winkler et al., 1990) and 
was found to be poorly stereoselective (Rogalska & al., 1990). Unlike pre-duodenal lipases, 
pancreatic lipase requires colipase—a pancreatic protein—as cofactor for its enzymatic 
activity (Fig.1). Colipase relieves phosphatidyl choline-mediated inhibition of the interfacial 
lipase–substrate complex, helps anchor the lipase to the surface and stabilizes it in the 
‘open’, active conformation (Brockman, 2000; Lowe, 1997). 
 
Fig. 1. 3-D Structure of the HPL-procolipase complex in the closed conformation (E) and in 
the open conformation (E*). These two diagrams show the conformational changes in the 
lid, the ǃ-5 loop and the colipase during interfacial activation (Adapted from Miled et al., 
2000 as cited in van Tilbeurgh et al., 1992; 1993).  
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The lipase gene family includes also two other pancreatic proteins: pancreatic lipase related 
proteins 1 and 2, with strong nucleotide and amino acid sequence homology to pancreatic 
triglyceride lipase. All three proteins have virtually identical three-dimensional structures 
(Lowe, 2000). Of the pancreatic triglyceride lipase homologues, only pancreatic lipase 
related protein 2 has lipase activity (Table 2). 
 
Enzyme Name Substrate specificity References 
Pancreatic lipase Triglycerides (lipid-droplet) Thirstrup & al., 1994 
 
Pancreatic lipase 




Inhibitory effect of HPL (regulatory 
effect of TG digestion in the duodenum?)
 
Crenon & al., 1998 
Berton & al., 2009 
Pancreatic lipase 
related protein 2 
(PLRP2) 
Broad range of substrate specificity 
Triglycerides (milk lipid-droplet) 
Synergistic effect of HPL (regulatory 
effect of TG digestion in the duodenum?)
Phospholipids 
Galactolipids 
Esters of vitamin A 




Thirstrup & al., 1994 
Sias & al., 2004 
Reboul & al., 2006 
 











Esters of lipid-soluble vitamins 
















Verheij & al., 1983 
Abbreviations: HPL, human pancreatic lipase; TG, triglycerides  
Table 2. Human pancreatic enzymes involved in lipid digestion 
It should be stressed that adult pancreas also produces an enzyme equivalent to the 
colipase-dependant pancreatic lipase (CDL) called bile-salt-stimulated lipase (BSSL) or 
carboxyl ester lipase (EC 3.1.1.1) (Hui & Howles, 2002). Originally discovered in milk of 
humans and various other primates (Swan & al., 1992), BSSL participates to the intestinal 
digestion of dietary lipids (Table 2). While colipase-dependent pancreatic lipase facilitates 
the uptake of fatty acids, bile-salt-stimulated lipase facilitates the uptake of free cholesterol 
from the intestinal lumen (Sahasrabudhe & al., 1998). A distinguishing feature of this 722 -
amino acid native protein is that it requires primary bile salts for the hydrolysis of 
emulsified long chain triacylglycerols (Sahasrabudhe & al., 1998). 
The exocrine pancreas secretes another group of phospholipid-hydrolyzing enzymes 
including phospholipase A1 (EC 3.1.1.32), and phospholipase A2 (EC 3.1.1.4). These 
enzymes are secreted in their zymogen form and activated by trypsin on entering the 
duodenum (Nouri-Sorkhabi & al., 2000). 
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PLA1 catalyzes the hydrolysis of fatty acids exclusively at the sn-1 position of 
phospholipids. A free fatty acid (FFA) and a lysophospholipid (lysoPL) are the products of 
this reaction. However, this class of phospholipase is not well understood, and no crystal 
structures exist. The assignment of a function for this pancreatic enzyme has yet to be firmly 
established (Richmond & Smith, 2011). 
In intraluminal digestion, phospholipase A2 is primarily responsible for hydrolyzing 
phosphatidyl-choline to 2-lysophophatidyl-choline. This reaction is important in triglyceride 
digestion as the amphipathic phosphatidyl-choline, in a manner similar to bile salts, will 
adsorb to the surface of the lipid droplets, preventing contact between the lipase-colipase 
complex and its lipid substrate. Hydrolysis of phosphatidyl-choline by phospholipase 2 will 
allow desorption of lysophosphatidyl-choline, which is water soluble. The subsequent 
mucosal absorption of lysophosphatidyl-choline is important in the generation of enterocyte 
phospholipids and lipoproteins and, thus, chylomicron formation (Nouri-Sorkhabi & al., 
2000). 
2.4 Hepatic lipase 
As the name suggests, hepatic lipase (EC 3.1.1.3) is synthesized mostly by hepatocytes in the 
liver and found localized at the surface of liver sinusoidal capillaries (Perret & al., 2002). The 
human hepatic lipase presents four glycosylation sites, which are localized at positions 20, 
56, 340, and 375, and a molecular mass around 65 kDa (Ben-Zeev & al., 1994 ; Wolle & al., 
1993). Together with lipoprotein lipase (LPL), hepatic lipase (HL) could be considered as a 
lipase of the vascular compartment (Perret & al., 2002). Unlike pancreatic lipase, hepatic 
lipase does not require a cofactor for its activity; is stable at high salt concentrations and is 
inactivated by sodium dodecyl sulfate (Mukherjee, 2003). HL exerts both triglyceride lipase 
and phospholipase A1 activities, and is involved at different steps of lipoprotein metabolism 
(Santamarina-Fojo & al., 2004). The preferred physiological substrate of hepatic lipase is 
triglyceride of intermediate density lipoprotein (IDL) particle, which it hydrolyses to form 
triglyceride-poor and cholesterol-rich low-density lipoprotein (LDL). Hepatic lipase also 
converts post-prandial triglyceride rich high-density lipoprotein (HDL) particle (i.e.HDL2) 
to post-absorptive triglyceride poor HDL (i.e. HDL3) (Mukherjee, 2003). 
2.5 Lipoprotein lipase 
Lipoprotein lipase (EC 3.1.1.34) (LPL) is a non-covalent homodimeric protein produced 
mainly by the adipose, heart and muscle tissue and to some extent by macrophages (Camp 
& al., 1990). LPL is secreted from parenchymal cells as a glycosylated homodimer, after 
which it is translocated through the extracellular matrix and across endothelial cells to the 
capillary lumen. After secretion, however, the mechanism by which LPL travels across 
endothelial cells is still unknown (Braun & Severeson 1992; Mead & al., 2002). The 
glycosylation sites of LPL are Asn-43, Asn-257, and Asn-359 (Mead & al., 2002). Lipoprotein 
lipase has multiple functional domains including lipid-binding, the dimer formation, 
heparin binding, cofactor interaction and fatty acid-binding domains (Santamarina-Fojo & 
Dugi, 1994). Interaction of the enzyme with the lipoprotein substrate takes place in the lipid-
binding domain. This results in a conformational change that leads to the movement of a 
short helical segment or ‘lid’ to expose the active site containing the Ser-Asp-His catalytic 
triad, where hydrolysis of triacylglycerol takes place (Emmerich & al., 1992). As a 
www.intechopen.com
Emerging Approaches for the Treatment of  
Fat Malabsorption due to Exocrine Pancreatic Insufficiency 
 
275 
homodimer, LPL has the dual function of triglyceride hydrolase and ligand/bridging factor 
for receptor-mediated lipoprotein uptake. Through catalysis, triacylglycerol present in very 
low-density lipoprotein (VLDL) and chylomicron particles is converted to triglyceride-poor 
intermediate-density lipoprotein (IDL) and chylomicron remnants, respectively (Mukherjee, 
2003). Apolipoprotein CII (ApoCII) present on VLDL particles is the co-factor required for 
activating the enzyme (Mukherjee, 2003).  
2.6 Endothelial lipase 
Endothelial lipase (EC 3.1.1.3) which was firstly characterized in 1999 was also added to the 
lipase gene family (Jaye & al., 1999). Mature endothelial lipase is a 68 kDa glycoprotein with 
five potential N-linked glycosylation sites (Yasuda & al., 2010). It has 44% primary sequence 
homology with lipoprotein lipase, 41% with hepatic lipase and 27% with pancreatic lipase 
(Choi & al., 2002). The enzyme is secreted by endothelial cells from various tissues like lung, 
liver, kidney and placenta. However, heart and skeletal muscles do not express endothelial 
lipase (Jaye & al., 1999). Endothelial lipase differs from the other enzymes of the lipase gene 
family in the sequence of the ‘lid’ domain. Its 19-residue ‘lid’ region is 3 residues shorter and 
less amphipathic than ‘lid’ region of lipoprotein or hepatic lipase indicating a different 
enzymatic function (Jaye & al., 1999). Indeed, unlike lipoprotein or hepatic lipases that have 
triacylglycerol lipase activity, endothelial lipase has primarily a phospholipase A1 activity. It 
was suggested that endothelial lipase plays a physiologic role in HDL metabolism probably by 
catalyzing hydrolysis of HDL phospholipids thereby facilitating a direct HDL receptor-
mediated uptake (Cohen, 2003). Endothelial lipase may also facilitate the uptake of 
apolipoprotein B-containing remnant lipoprotein. As the placental tissue abundantly expresses 
endothelial lipase, it may also have a role in the development of fetus (Choi & al., 2002). 
3. Human dietary lipid digestion process and regulation of pancreatic fluid in 
healthy state 
Protein digestion begins in the stomach with the concomitant action of hydrochloric acid 
and pepsin, continues with pancreatic proteases in the duodenum, and finishes with 
numerous brush border peptidases located all over the small intestine (Fieker & al., 2011 as 
cited in Alpers, 1994). Starch digestion begins in the mouth with salivary amylase, continues 
with pancreatic amylase, and ends with several intestinal brush border oligosaccharidases 
(Fieker & al., 2011 as cited in Alpers, 1994). In contrast, the majority of lipid digestion and 
absorption occurs between the pylorus and the ligament of Treitz. Prior to this step, 5% to 
40% of the dietary triglyceride acyl chains are released in the stomach by gastric lipase 
(Armand & al., 1994, 1996, 1999; Carrière & al., 1993b ; Hamosh, 1990) which continues its 
action in the duodenum together with pancreatic lipase until these enzymes are degraded 
by pancreatic proteases. Although a pH of 8 to 9 appears to be optimal for pancreatic lipase 
activity in vitro, bile salts allow the enzyme to work efficiently at a pH of 6 to 6.5 in vivo 
(Borgstrom, 1964; Carrière & al., 2005). HPL is responsible for the hydrolysis of 40% to 70% 
of triglycerides (Fig.2). 
The pancreatic lipase-related 2 protein (hPLRP2), with a broader substrate specificity, 
hydrolyzes milk triglycerides (Berton & al., 2009) phospholipids (Jayne & al., 2002; Lowe, 
2002; Thirstrup & al., 1994) galactolipids (Sias & al., 2004) and esters of lipid-soluble 
vitamins (Reboul & al., 2006). Carboxyl ester lipase (also called bile salt-stimulated lipase,  
www.intechopen.com
 




Fig. 2. Schematic representation of the relative contributions of HGL and HPL to the overall 
digestion of dietary triacylglycerides. On a weight basis, the ratio of pancreatic lipase to 
gastric lipase total secretory outputs was found to be around four after 3 hours of digestion. 
The level of gastric hydrolysis was calculated to be 10% of the acyl chains released from the 
meal triglycerides. Gastric lipase remained active in the duodenum where it might still 
hydrolyze 7.5% of the triglyceride acyl chains. Hence, globally, during the whole digestion 
period, gastric lipase hydrolyzes 17.5% of all the triglyceride acyl chains. (Reproduced from 
Carrière & al., 1993b). 
(BSSL)) will hydrolyze triglycerides, diglycerides, phospholipids, and esters of lipid-soluble 
vitamins and of cholesterol (Hui & Howles, 2002). Phospholipase A2 hydrolyzes 
phospholipids to lysophospholipids20 which is essential for an optimal absorption of lipid 
nutrients (Fieker & al., 2011, as cited in Tso, 1994). 
Products generated during lipolysis are solubilized in bile salts–mixed micelles and 
liposomes (vesicles) which allow absorption across the intestinal villi. Once absorbed, the 
digested lipids are converted back to triglycerides, phospholipids, and esters of cholesterol 
and of lipid-soluble vitamins, then packaged as chylomicrons and transported through the 
thoracic duct into the systemic circulation for delivery to various sites throughout the body 
(Fieker & al., 2011, as cited in Tso, 1994). 
To execute this digestive function, postprandial pancreatic juice secretion can increase up to 
1 to 2 L per day in response to physiologic stimuli, mainly secretin and vagal output (Lee & 
Muallem, 2009). Appropriate enzyme delivery in the duodenum is allowed through a 
specific orchestration of the pancreatic fluid secretion during the fed state. In fact, during the 
gastric phase, digestion of proteins by pepsin and of triglycerides by gastric lipase generates 
amino acids and free fatty acids, respectively (Fieker & al., 2011, as cited in Alpers, 1994). 
When delivered through the pylorus, they become powerful stimulants of the 
cholecystokinin hormone (CCK) produced by the duodenal endocrine cells which stimulates 
pancreatic enzymes secretion and controls the gastric emptying rate. The acidic pH of the 
chyme entering the duodenum stimulates the release of secretin, which increases the 
secretion of water and bicarbonate ions from the pancreas (Fieker & al., 2011 as cited in 
www.intechopen.com
Emerging Approaches for the Treatment of  
Fat Malabsorption due to Exocrine Pancreatic Insufficiency 
 
277 
Solomon, 1994). This gastric phase of digestion represents an important aspect in the overall 
postprandial regulation of pancreatic secretion. During the intestinal phase, 
enterohormones, such as CCK, together with neurotransmitters and neuropeptides further 
stimulate pancreatic secretion (Chey & Chang, 2001). Thus, digestive pancreatic enzyme 
response to a meal follows a specific pattern in which the degree and duration depend on 
nutrient composition, caloric content and physical properties of the meal. Enzyme secretion 
into the duodenum increases quickly reaching peak output within the first 20 to 60 minutes 
postprandially, then decreasing to a stable level before reaching an interdigestive level at the 
end of the digestive period, ie, about 4 hours after meal intake (Keller & Layer, 2005). 
4. Exocrine pancreatic insufficiency & fat malabsorption 
As previously described, the pancreas functions as the main factory for the digestive 
enzymes. The gland produces pancreatic juice that consists of a mixture of more than two 
dozen digestive enzymes in the pre-activated form, called zymogens. Zymogens are 
produced by acinar cells and mixed with a bicarbonate rich fluid that is produced by 
pancreatic ducts cells (Whitcomb & Lowe, 2007). Trypsin, chymotrypsin, amylase and lipase 
are responsible for the majority of the enzyme activity derived from the pancreas 
(Whitcomb & Lowe, 2007). Lipase is one of the most important enzymes because it plays a 
leading role in the digestion of fat, which is the highest dietary source of calories.  
Pancreatic exocrine insufficiency, partial or complete loss of digestive enzyme synthesis, 
occurs primarily in disorders directly affecting pancreatic tissue integrity (Table 3).  
 
Pancreatic parenchymal disease 
 
Chronic pancreatitis 












Short bowel syndrome 
Bariatric surgeries (eg, gastric bypass)
Table 3. Conditions Causing EPI (adapted from Keller et al., 2009). 
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It is most frequently due to chronic pancreatitis (in adults) or cystic fibrosis (in children) 
(Keller & al., 2009). Other pancreatic causes include acute pancreatitis, pancreatic tumors 
and pancreatic surgery (Table 3).  
While protein and starch digestion are usually maintained at a normal physiological level 
even in severe cases of pancreatic insufficiency, lipid malabsorption becomes the overriding 
problem and causes many of the clinical symptoms and nutritional deficiencies.  
4.1 Pathophysiology 
Clinically evident EPI occurs only when 90% of the function is lost and the secretion of 
pancreatic enzymes is less than 10% of normal (Lankisch & al., 1986; Layer & al., 1986). In 
chronic pancreatitis, an earlier decrease of lipase secretion is observed in comparison with 
amylase and protease. This is due to higher susceptibility of lipase to acidic pH caused by 
concomitant impairment of bicarbonate secretion, higher susceptibility of lipase to 
proteolytic destruction during small intestinal transit, additional acidic denaturation of bile 
acids and marked inhibition of bile acid secretion in malabsorptive states (Keller & Layer, 
2005). Hence, in case of EPI, fat malabsorption precedes malabsorption of proteins and 
carbohydrates and is clinically more apparent. Additionally, due to the low bicarbonate 
secretion, the intraduodenal pH may drop below 4 late postprandially, bile salts may 
precipitate which leads to a decrease in post- prandial duodenal lipid solubilisation and 
contribute to impaired lipolysis (Zentler-Munro & al., 1984). The increased presence of lipids 
and other nutrients in the distal small bowel causes significant alterations in gut motility 
leading to accelerated gastric emptying and intestinal transit. This results in a marked 
decrease in the time available for digestion and absorption of nutrients, which also 
contributes to the malabsorption (Layer & al. 1997). However, more than 80% of 
carbohydrates can be digested and absorbed in the absence of pancreatic amylase activity 
and the colonic flora can further metabolizes malabsorbed carbohydrates (Layer & al., 1986). 
By contrast, gastric lipase, the only extrapancreatic source of lipolytic activity in humans, 
does not compensate efficiently for pancreatic lipase deficiency although it may be elevated 
in patients with chronic pancreatitis compared to healthy individuals (Carrière & al., 1993b). 
That’s why fat malabsorption remains the first problem to be considered when treating EPI.  
4.2 Clinical symptoms and complications 
Maldigestion of fat results in steatorrhoea. In western countries steatorrhoea is diagnosed 
when daily stool fat content exceeds 7 g during ingestion of a diet containing 100 g fat per 
day. This corresponds to a decrease of the enteral absorption rate to less than 93% (Dimagno 
& al., 1973). Steatorrhoea causes symptoms such as foul-smelling, voluminous, greyish, fatty 
stools, abdominal cramps, bloating and chronic abdominal pain (Pasquali & al., 1996). It 
may also cause weight loss due to the loss of the highest dietary source of calories (fat 
contains 38 kJ/g, carbohydrates and protein contain 17 kJ/g) (Rosenlund & al., 1974). 
Steatorrhoea and weight loss are the overt clinical symptoms of EPI. They usually only 
occur if pancreatic enzyme secretion falls below 5–10% of normal levels (Keller & al., 2009).  
Due to fat malabsorption fat-soluble vitamins (A, D, E and K), magnesium, calcium and 
essential fatty and amino–acids are insufficiently resorbed (Dutta & al., 1982; Keller & al., 2009) 
which results in a variety of associated complications. Deficiencies in these vitamins and 
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nutrients may lead to tetany, glossitis, cheilosis, and in a more progressive stage, to peripheral 
neuropathy (Dimagno , 1993). Patients with PEI may exhibit low vitamin D levels and develop 
osteopathy, i.e. osteopenia, osteoporosis and osteomalacia. There are reports on vitamin A 
deficiency causing night-blindness, visual impairment and other ocular affections. As a 
consequence of vitamin E and K deficiencies neurologic symptoms or coagulopathy can occur 
(Keller & al., 2009). There seems also to be an increased risk for cardiovascular events in PEI, 
independent of life style factors (Gullo & al., 1996).  
4.3 Incidence and diagnosis 
The prevalence of EPI is increasing with the higher proportion of patients with cystic 
fibrosis who survive into adult life and the incidence of chronic pancreatitis, which rises in 
parallel with alcohol consumption. In fact, the incidence of cystic fibrosis is approximately 1 
in 2500 live births. The lack of chloride secretion in the pancreatic duct is responsible for 
severe exocrine pancreatic insufficiency in approximately 85% of CF newborns (Levy, 2011). 
In case of chronic pancreatitis, an incidence of 8.2 per 100 000 population per year and a 
prevalence of 26.4 cases per 100 000 along with a 3.6-fold increase in mortality in patients 
with alcohol-induced chronic pancreatitis compared with a population without chronic 
pancreatitis has been signaled (Keller & al., 2009). Hence, to avoid malnutrition related 
morbidity and mortality, it is pivotal to start treatment as soon as EPI is diagnosed. 
Several direct and indirect function tests are available for assessment of pancreatic function. 
Direct invasive function tests like the secretin-caerulein test are still the gold standard with 
highest sensitivity and specificity. However, their availability is limited to specialized 
centers, they are costly, time consuming and uncomfortable for the patient (Keller & al., 
2009). Determination of fecal elastase is convenient and widely available but its sensitivity is 
low in mild to moderate cases. Moreover, due to low specificity, it is of limited value for 
differential diagnosis in patients with diarrhea (Dominguez-Munoz & al., 1995; Stein & al., 
1996). Other non-invasive tests such as 13C-breath tests are becoming more important but 
are not widely established, yet (Dominguez-Munoz & al., 2007).  
5. Standard approaches for the treatment of fat malabsorption due to 
exocrine pancreatic insufficiency 
The main focus in the management of EPI is to prevent weight loss, EPI related symptoms, 
vitamin deficiencies, and to improve the patient’s nutritional status. Whatever the aetiology, 
oral pancreatic enzyme supplements are widely used as the first-line approach to treat 
malabsorption secondary to exocrine pancreatic insufficiency (Breithaupt & al., 2007).  
5.1 Formulations and galenic properties 
Pancreatic enzyme preparations (PEPs) are typically a mixture of porcine-derived pancreatic 
enzymes. These preparations, also called pancreatin, contain a variable mixture of protease, 
lipase and amylase depending on the brand. Various preparations are commercially 
available. The main formulations are immediate-release, enteric-coated microspheres and 
minimicrospheres, enteric-coated microtablets and enteric-coated microspheres with a 
bicarbonate buffer (Table 4). A Comprehensive table of these preparations has been 
summarized in other reviews (Krishnamurty & al., 2009, Ferrone & al., 2007). 
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Formulation Number of 
available products 
Product example (manufacturer) 
Immediate–release 
formulations 
6 Pancrelipase tablets (various manufacturers) 
Vikokase powder (Axcan Scandipharm) 
   
Enteric-coated 
microspheres 
24 Lipram capsules (Global Pharmaceuticals) 
Pangestym (Ethex) 




7 Pancrease (McNeil) 
Ultrase (Axcan Scandipharm) 
Enteric-coated 
minimicrospheres 




3 Pancrecarb (Digestive Care) 
Table 4. Commercially available pancreatic enzyme formulations (adapted from 
Krishnamurty et al., 2009) 
The uncoated formulations are susceptible to acidic inactivation in the stomach and are 
currently used largely in clinical practice to treat the pain of chronic pancreatitis and not 
malabsorption (Chauhan & Forsmark, 2010). The enteric-coated pancreatic enzyme 
formulations have been developed to solve problems associated with acid-mediated 
inactivation of pancreatic lipase, especially in patients with EPI who also show low pH 
values in the small intestine. First generation of these preparations was the enteric coated 
tablet with diameter of 11-20 mm. Due to their large size, these formulations did not empty 
into the duodenum as quickly as smaller food particles and did not show any additional 
benefits over conventional preparations (Meyer & al., 1988; Meyer & Lake, 1997). Next 
generation of enteric-coated preparations consist of capsules (over 2 mm in size) coated with 
acid resistant agents designed to release the enzyme between pH 5.0-5.5. No therapeutic 
benefit of these preparations was seen. Studies of labeled capsules suggest that even with 
varying sizes of microspheres, the ingested lipid may enter the duodenum in advance of the 
pancreatic enzyme (Meyer & Lake, 1997). Hence, newer formulations consisting of capsules 
containing mini-microspheres, pellets or micro-tablets of less than 2 mm in size were 
designed to promote an adequate intragastric mixture of exogenous enzymes with chyme. 
Whether the use of these enteric coated mini-microsphere preparations adds any special 
advantage over the existing treatment options remains, however, subject to great discussion 
(Halm & al., 1999; Stern & al, 2000). 
The most recent innovation in the formulation of pancreatic enzymes supplements has been 
the development of enteric-coated “buffered” micro-sphere preparations which have 1.5-2.5 
mEq of bicarbonate per capsule. Clinical trials conducted to compare these formulations to 
standard enteric coated microspheres showed controversy results (Brady & al., 2006; Kalnins 
& al., 2006).  
In Europe, availability of preparations varies by country and they are regulated nationally 
and not by the European Medicines Agency. In products in which the enzyme content has 
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been standardized, marked variability in particle size, enzyme release, and for some, acid 
stability has been noted and may result in differences in clinical effect (Walters & 
Littlewood, 1996; Aloulou & al., 2008; Löhr & al., 2009). In the United States, marked 
variation in the enzyme content of the various formulations especially with generic products 
has been attributed to a lack of stringent regulation (Fieker & al., 2011).  
5.2 Dosage recommendation and schedule of administration 
Some general guidelines are given in spite of the absence of an easy applicable and objective 
method to establish the adequate dose of oral pancreatic enzymes to treat exocrine 
pancreatic insufficiency. 
In general, the recommended dosage of Pancreatic enzyme supplements (PES) for a main 
meal (breakfast, lunch, or dinner) ranges from 25,000 to 75,000 units of lipase and from 
10,000 to 25,000 units of lipase for snacks, depending on the fat content of the meal (Sikkens 
et al., 2010). Initial dose must ensure supplementation of 60 UI/min of lipase activity in 
postparandial chyme throughout the digestive period; hence, dosing is adjusted considering 
this recommendation and the amount of lipase in the supplement (Krishnamurty et al., 
2009) but it is not recommended to exceed 10,000 units of lipase per kg of body weight per 
meal (Fieker et al., 2011). 
The timing of ingestion of the capsules is important to optimize therapeutic efficacy. A 
recent study compared three different administration schedules using enzyme replacement 
before, during or after meals. Better lipid digestion was found when giving enzymes during 
or after meals (Dominguez-Munoz & al., 2005).  
5.3 Efficacy assessment of the treatment with pancreatic enzyme supplements 
Numerous randomized placebo controlled trials have shown that treatment with pancreatic 
enzyme supplements improves steatorrhea, as measured by increased fat absorption, 
reduced fecal fat excretion, decreased stool weight and frequency, improved stool 
consistency and improved symptom scores (Guarner et al., 1993; O’keefe et al., 2001; 
Dominguez-Munoz et al., 2005; Safdi et al., 2006, Trapnell et al., 2009; Wooldridge et al., 
2009; Whitcomb et al., 2010). Enzyme supplements have been found to improve lipid 
malabsorption in children even those who are younger than 7 years old (Graff et al., 2010a, 
2010b). In yet other studies, increased cholesterol absorption and improved enterohepatic 
cycling of bile salts have been reported (Dutta et al., 1986; Vuoristo et al., 1992). Moreover, it 
has been demonstrated that improvement of lipid digestion contributes to effective 
correction of motility disorders (Mizushima et al., 2004). Altered levels of gastro-intestinal 
hormones were normalized (Nustede et al., 1991); accelerated gastric emptying and 
abnormal antroduodenal motility were corrected (Layer et al., 1997).  
Even though, randomized controlled trials have suggested, years ago, that non-enteric 
coated pancreatic enzyme supplements reduce pain in chronic pancreatitis (Isaksson et al., 
1983; Slaff et al., 1984), a more recent study did not support the use of these preparations for 
the relief of pain in all patients (Brown et al., 1997). Unfortunately, pancreatic enzyme 
supplements were reported to be not sufficient for correcting fat soluble vitamin deficiencies 
or B12 deficiency without simultaneous vitamin supplementation (Dutta et al., 1982; Bang et 
al., 1991).  
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The most surprising fact regarding efficacy assessment of this therapy is that few 
investigations are made considering nutritional status and quality of life improvements as 
well as weight gain (Czako et al., 2003; Trolli et al., 2001; Dominguez-Munoz, 2007). 
Reduction in stool fat achieved by pancreatic enzyme replacement therapy has not been 
proven by robust research to be correlated with a complete correction of nutritional 
deficiency in patients with pancreatic insufficiency. Accordingly, an overall assessment of 
this therapy efficacy is yet dependent on future demonstration of long-term interesting 
outcomes. 
5.4 Safety concerns, side effect and treatment failure  
Enzyme replacement therapy using pancrelipase (pancreatin) delayed-release capsules (i.e. 
Creon®, Solvay Pharmaceuticals, Inc., Marietta, GA, USA) have been available in the United 
States of America for more than 20 years with very few observed side effects (Krishnamurty 
et al., 2009). Meanwhile, allergic reactions to the porcine proteins and some others side 
effects may occur: Pancreatin extracts are prone to form insoluble complexes with folic acid 
resulting in folate deficiency (Russell & al., 1980). One serious adverse effect has been 
reported by Smyth et al. (1994, 1995). The authors described five children with cystic fibrosis 
in which a colonic obstruction developed due to fibrosing colonopathy (FC) after using very 
high doses of the enteric-coated micro- minisphere preparations (i.e. more than 20000 lipase 
units/capsule). Fortunately, the cases of reported FC have decreased considerably since the 
Medicine Control Agency (MCA) recommended in 1994 that the dose of pancreatic enzymes 
should not exceed 10,000 IU lipase/kg/day in patients with CF (Taylor , 2002 as cited in 
Medicine Control Agency, 1994). 
Recently, Axcan Pharma Inc. and its subsidiaries received safety update reports describing a 
total of 46 adverse events observed in a clinical study carried out between 01 November 
2008 and 31 May 2009 and involving three pancreatic enzyme preparations: ULTRASE®, 
VIOKASE® and PANZYTRAT® (Table 5). Fifty-three patients were enrolled, 40 of these 
patients completed the study. 
In most cases, adverse effects were single occurrences. Drug ineffectiveness was the most 
frequently reported adverse effect for ULTRASE® (Table 5). A lack of therapeutic effect was 
also reported for some other preparations (Kraisinger et al., 1994). In fact, among marketed 
PEPs, great variability in the amount of enzymes included in each capsule has been noted 
(Case & al., 2005; US Food and Drug Administration, 2006; Wooldridge & al., 2009) due in 
part to the manufacturer practice of overfilling capsules to account for enzyme degradation 
that occurs over the course of the product's shelf life (US Food and Drug Administration, 
2004). While instability of the enzymes results in delivery medications that contain less than 
the packaged amount of enzyme, the practice of “overfilling” in an effort to address enzyme 
degradation may result in excess enzyme content, resulting in formulations that deliver 
inadequate or excess amounts of enzyme. 
The possible safety risk posed by high-dose enzyme therapy, particularly fibrosing 
colonopathy , in combination with the issue of enzyme overfill, recently prompted the FDA 
to require the manufacturers of PEPs to demonstrate drug efficacy and safety in randomized, 
placebo-controlled trials before approval (Trapnell & al., 2009). The FDA ruled that 
manufacturers of pancreatic enzyme supplements must file new drug applications  
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Table 5. Adverse Events (Preferred Term) Recorded for Pancreatic Enzyme Preparations in 
the Axcan Pharma Safety Database Classified by System Organ Class from November 1, 
2008, to May 31, 2009 (Reproduced from Page 8 of the Safety Update for NDA 22-222 dated 
August 4, 2009). 
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 (NDA) to ensure consistent efficacy, safety, and quality of these agents (US Food and Drug 
Administration, 2006). Therefore, in order to comply with the FDA 2004 mandate, several 
studies have been recently conducted to ensure safety and effectiveness of some new 
reformulated pancreatic enzyme supplements such as Creon® 24,000 and EUR-1008 
(Zenpep™) (Wooldridge & al., 2009; Trapnell & al., 2009). Nevertheless, these products of 
animal origin present yet a risk of viral transmission. Accordingly, there remains a need for 
new alternatives to treat correctly exocrine pancreatic insufficiency. 
6. Enzyme replacement therapy: What’s in the pipeline? 
6.1 Bovine enzymes 
Even though bovine enzymes have been suggested as a potential alternative for individuals 
who refuse to consume porcine products for religious or other cultural reasons; there remain 
some safety concerns about transmittable pathogens such as Foot and mouth disease and 
Bovine spongiform encephalopathy from these preparations. Additionally, lipase activity is 
approximately 75% lower than the porcine preparations (Layer and Keller, 2003)  
6.2 Recombinant mammalian/human lipases 
Owing to rapid development of plant biotechnology in recent times, Merispase a 
recombinant mammalian gastric lipase was produced in transgenic corn by Meristem 
Therapeutics and proposed as new oral substitute for the treatment of pancreatic 
insufficiency. Dog gastric lipase was selected because it is naturally resistant to inactivation 
by stomach acids and maintains a high enzymatic activity after passage through the 
stomach. Enzyme expression was stable over 11 generations with an approximate level of 
1,000 mg kg-1 kernel (Shama & Peterson, 2008). According to Fieker et al. (2011), this 
approach could be problematic for several reasons: gastric lipase specific activity is about 10 
times lower than that of pancreatic lipase (measured on tributyrin), it is highly sensitive to 
trypsin proteolysis, and endogenous secretion of gastric lipase can be increased in patients 
with pancreatic insufficiency because of possible nutritional adaptation. Meanwhile, clinical 
trials showed that the recombinant gastric lipase is well tolerated and efficient when 
administered either alone or combined with porcine pancreatic extract to patients with 
cystic fibrosis (Fieker & al., 2011, as cited by Lenoir et al., 2006, 2008). The highest efficiency 
is obtained when 250 mg of recombinant gastric lipase is associated with low dose of 
pancreatic extract (Fieker & al., 2011, as cited by Lenoir et al., 2008). Despite these 
encouraging results, Mersitem therapeutics went out of business in September 2008 while 
the product was blocked in clinical phase II trial. 
Expected to offer superior safety by decreasing the risk of allergic reactions, recombinant 
human bile salt- stimulated lipase was suggested as promising candidate for the treatment of 
lipid malabsorption in pancreatic insufficiency. Human bile salt-stimulated lipase is naturally 
acid resistant and able to: (i) hydrolyze triglycerides and phospholipids (Lindquist & Hernell, 
2010) (ii) generate lysophospholipids necessary for an efficient lipid absorption rate by the 
small intestine (Fieker & al., as cited by Tso, 1994) (iii) participate in chylomicron assembly and 
secretion through its ceramidase activity (Hui and Howles, 2002). For these reasons, Swedish 
Orphan Biovitrum - a leading company focused on treatment of rare diseases developed two 
preparations of recombinant bile salt-stimulated lipase: Kiobrina for preterm infants and 
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Exinalda for cystic fibrosis patients. A phase I clinical trial showed that addition of 
recombinant bile salt-stimulated lipase to standard pancrelipase (Creon) enabled a dose 
reduction of pancrelipase. The treatment had the advantage of restoring a normal level and 
pattern of plasma chylomicron secretion (Fieker & al., 2011, as cited by Strandvik et al., 2004). 
The combined results from two Phase II studies evaluating Kiobrina in preterm infants 
demonstrated an increase in growth velocity and uptake of long chain polyunsaturated fatty 
acids such as docosahexanoic acid and arachidonic acid. The safety and tolerability profile of 
rhBSSL added to formula was similar compared to placebo (Maggio et al., 2010). Based on 
these encouraging results, Swedish Orphan Biovitrum enrolls in August 2011 the first patient 
in Kiorbina phase III clinical trial. An open-label exploratory phase II study on Exinalda 
(rhBSSL) in patients with cystic fibrosis and pancreatic insufficiency has been completed. The 
aim was to study the effect of Exinalda on fat absorption as well as safety in this patient 
population. The results showed that Exinalda is safe and tolerable at a dose level of 170 mg 
three times a day. In terms of efficacy (coefficient of fat absorption CFA) the primary endpoint 
was not met. Swedish Orphan Biovitrum is now assessing options to continue the 
development (Swedish Orphan Biovitrum website www. sobi.com). 
6.3 Microbial and plant derived lipases 
With the aim of developing porcine-free enzyme supplements and in order to avoid the 
short-life of lipolytic enzymes of pancreatic origin, microbial lipases of fungal or bacterial 
origin were suggested for replacement therapy. Therefore, potential efficacy of many fungal 
Lipases derived from Aspergillus niger (Griffin & al., 1989), Rhizopus arrhizus (Iliano & 
Lodewijk, 1990), Rhizopus delemar (Galle & al., 2004 ), Candida cylindracea (Schuler & Schuler, 
2008) and Yarrowia lipolytica (Turki & al., 2010a) was investigated. The Yarrowia lipolytica 
lipase seemed to be of potential interest because of its acid and protease-stable properties 
and its resistance to the detergent action of bile salts as shown in vitro (Turki & al., 2010a). 
Supporting its use as a pharmaceutical, safety assessment of the enzyme in rats showed that 
there were no toxicologically severe changes in clinical signs, growth, hematology, clinical 
chemistry, organ weight and pathology related to oral administration of Yarrowia lipolytica 
lipase in animals (Turki & al., 2010b). Actually, a substitute for EPI treatment based on 
Lip2p is under investigation by Laboratoire Mayoly Spindler, a French pharmaceutical 
company specialized in gastroenterology therapeutics (Fickers & al., 2011, as cited in 
http://www.mayoly-spindler.com/). The process development in cGMP conditions for the 
production of the Yarrowia lipolytica MS1819 lipase was completed in 2009 with the Swiss 
biotech company DSM Nutritional Product Ltd (Fickers & al., 2011, as cited in 
http://www.dsm.com, press release, December 22th, 2009). In 2010, a drug development 
partnership was established with Protea Biosciences to initiate phase I/IIA clinical trials in 
France with the aim of demonstrating safety and proof-of-concept of the therapeutic use of 
this recombinant lipase (Fickers & al., 2011).  
A pipeline preparation Liprotamase (formerly known as ALTU 135 and Trizytek) containing 
bacterial lipase, fungal protease and amylase was developed by Eli Lilly company (Eli Lilly, 
IN, USA, www. Lilly.com). An open-label Phase III safety study was carried out in order to 
evaluate 214 patients, of which 145 CF patients, ages 7 and above, completed 12 months of 
treatment with Liprotamase. Investigators found that 96 percent of all CF patients who 
received liprotamase for 12 months maintained or gained weight. Based on key nutritional 
parameters, the study showed that patients who completed 12 months of treatment with 
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liprotamase demonstrated that they maintained their nutritional status; and survival in 
people living with cystic fibrosis was maintained too (Borowitz & al., 2011). Subsequent to 
the completion of the stage III clinical study on liprotamase, the drug's manufacturer 
submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for 
approval. However, on January 13th of this year, the FDA panel stated that he was not 
convinced that Liprotamase was any better than the current pancreatic enzyme products 
available now. The manufacturer disclosed that another clinical trial must be conducted 
before the FDA will consider the approval of this drug (Eli Lilly, IN, USA, www. Lilly.com). 
In yet other approaches, plant acid-stable lipases were suggested as good alternatives to 
porcine preparations. Hence, considerable attention has focused in these enzymes and 
suitable techniques for isolating and purifying them have been well documented. A lipase 
sourced from Carica papaya latex has been recently proposed as suitable candidate for use as 
a therapeutic tool in patients with pancreatic exocrine insufficiency (Abdelkafi et al., 2009). 
The enzyme showed several biochemical properties enabling it to act in the gastro-intestinal 
tract like mammalian digestive lipases (Abdelkafi et al., 2009): (i) its activity on long-chain 
Triacylglycerols reaches an optimum at pH 6.0 in the presence of bile, (ii) it is only weakly 
inhibited by bile salts, (iii) it shows a similar pattern of regioselectivity to that of human 
pancreatic lipase, generating 2-Mono acylglycerol and free fatty acids (FFA), the lipolysis 
products absorbed at the intestinal level, and (iv) it shows significant levels of stability and 
activity at low pH values at a temperature of 37 °C. Therefore, Carica papaya lipase seems to 
be tailored to act optimally under the physiological conditions pertaining in the gastro-
intestinal tract. However, its sensitivity to digestive proteases still needs to be tested. 
6.4 Future therapies and new research areas 
Development of non-porcine enzyme replacement therapies is currently extended to new 
research areas including design, by direct molecular evolution, of human pancreatic lipase 
variants that display lipolytic activity at acidic pH higher than that of the native enzyme. 
Colin et al. (2008) investigated, first, the feasibility of altering the pH optimum of pancreatic 
lipase to improve its performances in the intestinal conditions of cystic fibrosis by site-
directed mutagenesis. Later, they demonstrated that directed molecular evolution approach 
combined to a sensitive screening strategy could be useful to improve pancreatic lipase 
activity at acidic pH. The authors showed that a single round of random mutagenesis was 
successful in identifying lipase variant with approximately 1.5-fold increased activity at low 
pH (Colin et al., 2010).  
Future therapies may also include structuring food emulsions and creation of functional 
dietary lipids that are more effectively digested. This new area of research could 
substantially help patient suffering from pancreatic insufficiency with the design of specific 
more digestible or absorbable lipid sources. Hence, the addition of specific phospholipids 
able to enhance lipase activity in enzyme supplements or in formula would both increase 
lipase activity and, in parallel, enhance lipid nutrient absorption (Fieker et al., 2011). 
7. Conclusion 
Pancreatic exocrine insufficiency is a condition commonly associated with diseases such as 
pancreatitis or cystic fibrosis. When pancreatic insufficiency is severe, impaired absorption 
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of nutrients by the intestines may result, leading to deficiencies of essential nutrients and the 
occurrence of loose stools containing unabsorbed fat (steatorrhea). A shortage of the 
digestive enzymes necessary to break down food is the main cause of this dietary 
malabsorption. Unlike protein and starch digestion, lipid malabsorption is the overriding 
problem and the main cause of clinical symptoms and nutritional deficiencies. Until 
recently, approaches used to address problem of fat malabsorption due to pancreatic 
insufficiency have been focusing primarily on oral administration of exogenous pancreatic 
enzymes extracted from porcine source. Standard clinical practices dictate administration of 
lipase 25,000-75,000 units/meal by using pH-sensitive pancrelipase microspheres, along 
with dosage increases, compliance checks, and differential diagnosis in cases of treatment 
failure. Various pancreatin preparations are available, however, differences in galenic 
properties and release kinetics and other factors such as early acid inactivation, under 
dosage and patient incompliance may decrease clinical efficacy of the treatment. The FDA 
decreed that all manufacturers of pancreatic enzyme supplements must file new drug 
applications (NDA) to ensure consistent efficacy, safety, and quality of these agents. 
Accordingly, improved approaches to treat efficiently problem of fat malabsorption 
secondary to pancreatic insufficiency are investigated. New alternatives of enzyme 
substitution therapy are being developed. Emerging therapeutic landscape includes use of 
porcine free - lipase preparations. Enzyme supplements either from human, mammalian, 
microbial or plant origins are wisely suggested. Interestingly, newest approaches state the 
design of acid -stable variants of human pancreatic lipase as well as creation of functional 
dietary food with specific more digestible/absorbable lipid sources. However, how these 
pipeline therapies may help meet the ongoing challenges in treating lipid malabsorption in 
patients with pancreatic insufficiency and improve the long-term outcomes of these patients 
remains yet to be assessed.  
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